A case of acquired rifampin resistance in Mycobacterium bovis bacillus Calmette-Guérin-induced cystitis: Necessity for treatment guidelines

4Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

A case of presumed bacillus Calmette-Guérin (BCG) cystitis in an elderly female patient following direct intravesical BCG instillation treatment for papillary transitional cell carcinoma is reported. The organism cultured from urine samples was eventually identified as a rifampin-resistant Mycobacterium bovis BCG isolate. Because the patient had received rifampin monotherapy during the course of treatment for presumed BCG disease, the clinical picture favoured acquired rifampin resistance. Sequencing of the target gene for rifampin (rpoB) confirmed a known mutation responsible for conferring high levels of resistance to both rifampin and rifabutin (Ser531Tyr). To the authors' knowledge, this is the first reported case of M bovis BCG disease in a non-HIV patient where the organism had acquired drug resistance to rifampin, and the second reported case of M bovis BCG that had acquired drug resistance. The present case demonstrates the necessity to re-evaluate appropriate guidelines for the effective treatment of BCG disease. ©2006 Pulsus Group Inc. All rights reserved.

Author supplied keywords

Cite

CITATION STYLE

APA

Wolfe, J. N., Blackwood-Antonation, K. S., Sharma, M. K., & Cook, V. J. (2006). A case of acquired rifampin resistance in Mycobacterium bovis bacillus Calmette-Guérin-induced cystitis: Necessity for treatment guidelines. Canadian Journal of Infectious Diseases and Medical Microbiology, 17(3), 183–185. https://doi.org/10.1155/2006/263932

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free